By Ben Butkus
A new study provides further support for MDxHealth's PredictMDx brain cancer test, which predicts which patients will respond to the alkylating chemotherapy temozolomide.
Asuragen said that that in the second half of this year it will release research-use-only reagents for evaluating FMR1 methylation status in the hopes of obtaining independent validation of the technology.
Exact has been evaluating several MDxHealth methylation biomarkers, among other biomarkers, as well as its methylation-specific PCR technology, under a previous licensing agreement.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.